Included in the formulation
АТХ:G.02.C.X Other drugs for use in gynecology
Pharmacodynamics:Has an estrogen-like, uterotonic effect. Affects the hypothalamic centers and gonadotropic function of the pituitary gland. Estrogenic activity does not possess, but takes part in the implementation of feedback (both positive and negative) in the hypothalamus-pituitary-ovary system, normalizing its functions. Increases the sensitivity of the myometrium to oxytocin. Strengthens utero-placental circulation, transport function of the placenta and supply of the fetus with oxygen and nutrients. It causes lipid-lowering effect, increases the blood levels of beta-lipoproteins, increases the sensitivity of tissues to insulin and the utilization of glucose.
Pharmacokinetics:Not studied.
Indications:Tablets: climacteric syndrome, manifested by "hot flashes", sweating, sleep disturbances, irritability, depression, forgetfulness, degenerative changes in the skin and mucous membranes (thinning of the skin, wrinkles, dry mucous membranes of the urogenital tract).
Solution: weakness of labor (preferably in combination with other drugs that accelerate labor activity, for example, oxytocin), a delayed pregnancy, intrauterine fetal asphyxia.
XIV.N80-N98.N95.1 Menopause and menopause in women
XV.O30-O48.O48 Mature pregnancy
XV.O60-O75.O62.2 Other types of weakness in labor
XVI.P20-P29.P20.9 Intrauterine hypoxia, unspecified
Contraindications:Hypersensitivitya massive blood loss in the parturient woman, a premature detachment of the normally located placenta.
Carefully:Renal failure, impaired liver function, hyperlipoproteinThe empire.
Pregnancy and lactation:The category of FDA recommendations is not defined. Adequate and well-controlled studies in humans and animals have not been conducted.
There is no information on the penetration into breast milk. For the duration of treatment, breastfeeding should be discontinued.
Dosing and Administration:Intravenous, intramuscular, orally.
With signs of fetal or fetal asphyxia, which begins to threaten, or if the labor is weak, intravenously slowly in a dose of 20-40 mg (2-4 ml of 1% solution); with intrauterine asphyxia can be administeredpre-diluted solution (better in 20-40 ml of 20% glucose solution); injections can be repeated at intervals of 30-60 minutes, but not more than 5 injections.
For the prevention of fetal asphyxia: intramuscularly or intravenously, 10-20 mg (1-2 ml of 1% solution) once a day.
With climacteric syndrome: inside, regardless of food intake, 50-100 mg 1-2 times a day, the course of treatment - 30-40 days.
Side effects:Nausea, vomiting, dizziness, rashes, swelling of the eyelids; with prolonged use - metrorrhagia, cholestatic jaundice.
Overdose:Symptoms: metrorrhagia, hemorrhagic shock.
Treatment: withdrawal of the drug, blood transfusion, parenteral administration of blood substitutes.
Interaction:Strengthens the action of oxytocin, diuretic, antiarrhythmic, antihypertensive drugs, anticoagulants; weakens the effect of drugs of male sex hormones. Folic acid and thyroid hormone drugs increase effectiveness.
Special instructions:No data.